X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Organon will pursue sustainable growth in Women’s Health led by patent-protected Nexplanon (etonogestrel implant) franchise and fueled by its leading contraceptive and fertility businesses. It expects to establish a leading position in Biosimilars focusing on oncology.
Lead Product(s): Etonogestrel
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Nexplanon
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Organon
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Demerger June 03, 2021
Details:
Organon’s commercial strategy will center around Nexplanon (etonogestrel implant), its long-active reversible contraceptive, that delivered approximately $1.6 billion in global sales in 2020.
Lead Product(s): Etonogestrel
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Nexplanon
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing May 03, 2021
Details:
Mithra grants license to Zentiva for commercialization of its vaginal contraceptive ring in three key European markets.
Lead Product(s): Etonogestrel,Ethinyl Estradiol
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Myring
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Zentiva
Deal Size: $2.2 million Upfront Cash: Undisclosed
Deal Type: Agreement July 06, 2020
Details:
Under the terms of this agreement, Gynial will distribute Myring™ in Switzerland, where the Swiss contraceptive rings market is worth EUR 8 million per year.
Lead Product(s): Etonogestrel,Ethinyl Estradiol
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Gynial
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 05, 2020
Details:
Merck will retain its current growth pillars of Oncology, Vaccines, Hospital and Animal Health and continue to invest in research and development of breakthrough innovations across all areas of science.
Lead Product(s): Etonogestrel
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Nexplanon
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $9.0 billion Upfront Cash: Undisclosed
Deal Type: Demerger February 05, 2020
Details:
Under the terms of the agreement, Farmitalia will distribute Myring™ in Italy, which is the third largest worldwide vaginal contraceptive ring market in terms of sales value and volume, after the US & Germany.
Lead Product(s): Etonogestrel,Ethinyl Estradiol
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Farmitalia
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 21, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
